Daniel H.D. Gray
YOU?
Author Swipe
View article: Repurposing BH3 mimetics to deplete tumour-infiltrating regulatory T cells and enhance anti-tumour immunity in non-small cell lung cancer
Repurposing BH3 mimetics to deplete tumour-infiltrating regulatory T cells and enhance anti-tumour immunity in non-small cell lung cancer Open
Tumour-infiltrating FOXP3 + regulatory T cells (Treg) exert suppression of anti-tumour immunity in non-small cell lung cancer (NSCLC), contributing to poor prognosis and immunotherapy resistance. The BCL-2 family pro-survival pr…
View article: Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer Open
Immune checkpoint inhibitors have emerged as a potent new class of anticancer therapy. They have changed the treatment landscape for a range of tumors, particularly those with a high mutational load. To date, however, modest results have b…
View article: Molecular determinants of brain-resident CD8<sup>+</sup> T cell formation and function
Molecular determinants of brain-resident CD8<sup>+</sup> T cell formation and function Open
Tissue-resident memory T (Trm) cells are strategically located to provide frontline protection upon antigen re-encounter while possessing tissue-specific transcriptional programs. Whether brain Trm cells similarly adapt to their tissue env…
View article: Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo
Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo Open
This study investigated preventative and therapeutic agents against human T cell lymphotropic virus type-1 subtype-C (HTLV-1c) infection. We established and characterized a humanized mouse model of HTLV-1c infection and identified that HTL…
View article: Deconstructing the Thymic Microenvironment Through Genesis to Senescence
Deconstructing the Thymic Microenvironment Through Genesis to Senescence Open
The thymus is essential for adaptive immunity, orchestrating the differentiation of hematopoietic progenitors into various T‐cell lineages. Thymic epithelial cells (TECs) impart this unique function by mediating the major checkpoints in T‐…
View article: Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer
Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer Open
View article: Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosis
Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosis Open
View article: Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia Open
Venetoclax, a first-in-class BH3 mimetic drug that targets B-cell lymphoma-2 (BCL-2), has improved the outcomes of patients with chronic lymphocytic leukemia (CLL). Early measurements of the depth of the venetoclax treatment response, asse…
View article: Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosis
Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosis Open
Mesenchymal stromal cells (MSCs) exert broad therapeutic effects across a range of inflammatory diseases. Their therapeutic properties, largely mediated by secreted factors, can be enhanced by pre-exposure to inflammatory cytokines, a conc…
View article: B cells targeting parasites capture spatially linked antigens to secure T cell help
B cells targeting parasites capture spatially linked antigens to secure T cell help Open
Our understanding of T-cell-dependent humoral responses has been largely shaped by studies involving model antigens such as recombinant proteins and viruses 1,2 . In these contexts, B cells internalize the entire antigen or pathogen, and p…
View article: Age-related epithelial defects limit thymic function and regeneration
Age-related epithelial defects limit thymic function and regeneration Open
The thymus is essential for establishing adaptive immunity yet undergoes age-related involution that leads to compromised immune responsiveness. The thymus is also extremely sensitive to acute insult and although capable of regeneration, t…
View article: Early cytokine-driven adaptation of survival pathways in lymphoid cells during targeted therapies
Early cytokine-driven adaptation of survival pathways in lymphoid cells during targeted therapies Open
Venetoclax, a first-in-class BH3 mimetic drug targeting BCL-2, has improved outcomes for patients with chronic lymphocytic leukemia (CLL). Early measurements of the depth of the venetoclax treatment response, assessed by minimal residual d…
View article: Author Correction: CIS is a potent checkpoint in NK cell–mediated tumor immunity
Author Correction: CIS is a potent checkpoint in NK cell–mediated tumor immunity Open
View article: Programmed death receptor 1 (PD‐1) ligand Fc fusion proteins reduce T‐cell proliferation <i>in vitro</i> independently of PD‐1
Programmed death receptor 1 (PD‐1) ligand Fc fusion proteins reduce T‐cell proliferation <i>in vitro</i> independently of PD‐1 Open
Programmed death receptor 1 (PD‐1) is an inhibitory receptor on T cells shown to restrain T‐cell proliferation. PD‐1 immune checkpoint blockade has emerged as a highly promising approach in cancer treatment. Much of our understanding of th…
View article: Molecular control of the lymphocyte death timer
Molecular control of the lymphocyte death timer Open
When stimulated, individual lymphocytes program times for division and death that are inherited within families, revealing a common timing mechanism transmitted over generations. Here we describe a threshold-based mechanism for the time to…
View article: Expansion of MAIT cells in the combined absence of NKT and γδ-T cells
Expansion of MAIT cells in the combined absence of NKT and γδ-T cells Open
View article: Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer
Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer Open
View article: Distinct subpopulations of DN1 thymocytes exhibit preferential γδ T lineage potential
Distinct subpopulations of DN1 thymocytes exhibit preferential γδ T lineage potential Open
The αβ and γδ T cell lineages both differentiate in the thymus from common uncommitted progenitors. The earliest stage of T cell development is known as CD4 - CD8 - double negative 1 (DN1), which has previously been shown to be a heterogen…
View article: Tables S1-5 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Tables S1-5 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Open
Supplementary Tables S1-5
View article: Figures S1-8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Figures S1-8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Open
Supplementary Figures
View article: Table S6 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Table S6 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Open
Supplementary Table S6
View article: Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia Open
The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leukemia (CLL). However, despite continuous daily treatment, leukemia recurs in most patients. To investigate the…
View article: Table S7 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Table S7 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Open
Supplementary Table S7
View article: Tables S1-5 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Tables S1-5 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Open
Supplementary Tables S1-5
View article: Table S9 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Table S9 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Open
Supplementary Table S9
View article: Figures S1-8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Figures S1-8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Open
Supplementary Figures
View article: Data from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Data from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Open
Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. Using a phase Ib 3 + 3 dose-escalation and expansion study design, 33 patients with ER and BCL2-positi…
View article: Supplementary Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Supplementary Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia Open
Supplementary Material
View article: Table S8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Table S8 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer Open
Supplementary Table S8
View article: Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia Open
The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leukemia (CLL). However, despite continuous daily treatment, leukemia recurs in most patients. To investigate the…